Skip to main content

Clinical trial IJB_2732

A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors

Cancers
Organ solid tumors
Trial status Trial open for recruitment
Trial type
Prospective interventional
Phase Trial phase 1a/1b
Academic trial Non
Sponsor Lilly
EudraCT Identifier 2017-002693-39 
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03343613
Inclusion criteria Metastatic Biopsy mandatory
Last update

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more